Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
- Resource Type
- Article
- Source
- In
International Immunopharmacology 30 May 2024 133 - Subject
- Language
- ISSN
- 1567-5769